New Zealand markets closed

PFE Sep 2024 47.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.03000.0000 (0.00%)
As of 10:22AM EDT. Market open.
Full screen
Previous close0.0300
Open0.0300
Bid0.0000
Ask0.1500
Strike47.50
Expiry date2024-09-20
Day's range0.0300 - 0.0300
Contract rangeN/A
Volume50
Open interest250
  • Reuters

    Pfizer vs Moderna battle over COVID vaccine patents begins in UK

    Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday. Pfizer and its German partner BioNTech sued Moderna at London's High Court in September 2022, seeking to revoke patents held by Moderna, which hit back days later alleging its patents had been infringed. Moderna says Pfizer and BioNTech copied mRNA advances it had pioneered and patented well before the COVID-19 pandemic began in late 2019.

  • Zacks

    Pfizer (PFE) Rises Higher Than Market: Key Facts

    Pfizer (PFE) reachead $26.26 at the closing of the latest trading day, reflecting a +1% change compared to its last close.

  • Business Wire

    European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options

    NEW YORK, April 22, 2024--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO® (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis. It is also indicated for the treatment of infections due to aerobic Gram-negative